Clinical trials: Cancer Survivorship
Cervical Cancer Recurrent or Persistent, Palliative Treatment
Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma
This study evauates the global survival of patients following administration of mAb Nimotuzumab hR3 + chemotherapy in the treatment of cervical cancer in first line therapy, after relapsing from chemo-radiotherapy.
- Conditions
- Cervical Cancer Recurrent or Persistent, Palliative Treatment, Monoclonal Antibody in Cervical Cancer Treatment
- Trial name
- NCT02083211
- Testing
- mAb Nimotuzumab
- Where
- Mexico
- Volunteers
- 168 people
- Sponsor
- National Institute of Cancerología
Glioblastoma, Glioblastoma Multiforme
The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients.
The trial is designed as a multicenter randomized controlled study. 246 patients with presumed Glioblastoma Multiforme in eloquent areas on diagnostic MRI will be selected by the neurosurgeons according the eligibility criteria…
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Astrocytoma, Grade IV
- Trial name
- SAFE (NCT03861299)
- Testing
- Awake craniotomy, Craniotomy under general anesthesia
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 246 people
- Sponsor
- Jasper Gerritsen
Gastric Cancer
Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSK
A randomized controlled study is conducted on patients with resected gastric cancer assigned to postoperative adjuvant therapy of TS-1 alone or PSK combined with TS-1, with the objective to examine or validate the outcome, QOL…
- Trial name
- NCT00216034
- Testing
- Tegafur-gimeracil-oteracil potassium (TS-1), Krestin (PSK)
- Where
- 42 sites in Japan
- Volunteers
- 255 people
- Sponsor
- Hokuriku-Kinki Immunochemotherapy Study Group
Cancer
Prognosis and Survival Estimates in Palliative Therapy
The accuracy of clinical survival estimates is tested in comparison to objective prognostic scores.
- Trial name
- NCT00871520
- Testing
- no specific interventions
- Where
- 3 sites in Germany
- Volunteers
- 612 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Glioma
Tessa Jowell BRAIN MATRIX - Platform Study
The main aim of the Tessa Jowell BRAIN MATRIX - Platform Study is to more precisely determine the exact type of tumour patients have by developing the essential infrastructure to provide rapid and accurate molecular diagnosis.
- Trial name
- BRAIN MATRIX (NCT04274283)
- Testing
- Matched Tumour and Blood Sample - Research Pathway, Matched Tumour and Blood Sample - NHS GMS pathway
- Where
- 14 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- University of Birmingham
Lymphoma, Malignant Solid Neoplasm
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
This phase III trial compares the effect of geriatric evaluation and management with survivorship health education (GEM-S) to usual care on patient-reported physical function in older survivors of cancer.
- Trial name
- GEM-S (NCT05006482)
- Testing
- Best Practice, Comprehensive Geriatric Assessment, Educational Intervention
- Where
- 45 sites in United States
- Volunteers
- 668 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Gastric Cancer
Postoperative Sequence Chemoradiotherapy Compared With Chemotherapy Alone for Advanced Gastric Cancer
Gastric cancer is one of the most prevalent malignancies in China; the survival rate remains poor despite potentially curative resections.
- Trial name
- NCT01197118
- Testing
- sequence chemoradiotherapy, chemotherapy alone following radical resection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Huazhong University of Science and Technology
Breast Neoplasm
Post-treatment Care of Breast Cancer Survivors
The overall goal of this proposal is to improve the post-treatment care of breast cancer survivors and to understand the barriers to optimal post-treatment care in Latina and Non-Hispanic women.
- Trial name
- NCT00821288
- Testing
- Survivorship Intervention, Facing Forward
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Columbia University
Breast Cancer, HER2-low Breast Cancer
Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer
This is a cross-sectional and an observational study, investigator-initiated study in HER2-low breast cancer patients. Approximately 255 subjects with HRD (homologous recombination deficiency) assessment will be enrolled in this…
- Trial name
- NCT05466786
- Testing
- Standard Management
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cervical Cancer
Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients
To evaluate if adjuvant concurrent chemoradiotherapy is associated with a recurrence-free survival benefit in comparison with radiotherapy alone in selected intermediate risk cervical cancer after radical surgery.
- Trial name
- NCT05277688
- Testing
- adjuvant concurrent chemoradiotherapy, radiotherapy
- Where
- 2 sites in China
- Volunteers
- 340 people
- Sponsor
- Ruijin Hospital
Ovarian Cancer, Breast Cancer
Comprehensive Outcomes for After Cancer Health
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer.
- Conditions
- Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer
- Trial name
- COACH (NCT05349227)
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- 7 sites in United States
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- Pack Health
Glioblastoma
Exercise in Patients With Glioblastoma
Patients with newly-diagnosed GBM will be given personalized exercise regimes during concurrent chemo-radiation and up to 3 months later.
- Trial name
- NCT03390569
- Testing
- Exercise
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- University Health Network, Toronto
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer
This 2 arm study will compare the efficacy and safety of sequential treatment with Tarceva and gemcitabine, and of gemcitabine monotherapy, as first line treatment of elderly patients, or patients with ECOG performance status of…
- Trial name
- NCT00940875
- Testing
- erlotinib [Tarceva], gemcitabine
- Where
- 17 sites in Australia
- Volunteers
- 54 people
- Sponsor
- Hoffmann-La Roche
Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
Multimodal treatment combining surgery with chemotherapy and/or radiotherapy is necessary to improve the chances of survival in patients with locally advanced thoracic esophageal cancer.
- Trial name
- HCHTOG1903 (NCT04138212)
- Testing
- Paclitaxel, Cisplatin, neoadjuvant chemoradiation therapy
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Henan Cancer Hospital
Hematologic Neoplasm, Hematopoietic Stem Cell Transplantation
HematoCare: Feasibility of a Survivorship Care Plan for Hematologic Cancer Patients Undergoing HSCT
This is a feasibility study to implement a Survivorship Care (SC) Plan for patients with hematologic cancer undergoing hematopoietic stem cell transplantation (HSCT).
- Conditions
- Hematologic Neoplasm, Hematopoietic Stem Cell Transplantation, Survivorship, Cancer Survivorship
- Trial name
- HematoCare (NCT07579065)
- Testing
- Survivorship Care (SC) Plan
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
This study will evaluate zoledronic acid's anti-cancer effects and Circulating Tumor Cell (CTCs) measurements in patients with HER2-negative metastatic breast cancer without bone metastasis.
- Trial name
- MACS1295 (NCT01129336)
- Testing
- Zoledronic acid, Standard Therapy
- Where
- 33 sites in United States
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Gastric Cancer
Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer
Elderly patients are generally underrepresented in the study populations of combination chemotherapy trials. In gastric cancer patients, oxaliplatin has shown a more favorable toxicity profile than cisplatin.
- Trial name
- MATURE (NCT02002195)
- Testing
- FOLFOX, Capecitabine
- Where
- 2 sites in Italy
- Volunteers
- 47 people
- Sponsor
- International Group of Endovascular Oncology
Sickle Cell Disease, Thalassemia
Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients
Red Blood Cell - IMProving trAnsfusions for Chronically Transfused recipients (RBC-IMPACT) is an observational cohort study to assess donor, component, and recipient factors that contribute to RBC efficacy in chronically and…
- Conditions
- Sickle Cell Disease, Thalassemia, Pediatric Cancer
- Trial name
- RBC-IMPACT (NCT05255445)
- Testing
- Red Blood Cell (RBC) Transfusion
- Where
- 14 sites in United States, Brazil
- Volunteers
- 157 people
- Sponsor
- Westat
Colorectal Cancer (Diagnosis)
The Effectiveness of the mHealth Survivorship Program on Enhancing Health-related Quality of Life Among Colorectal Cancer Survivors
The goal of this clinical trial is to evaluate the effectiveness of the mHealth survivorship program in enhancing health-related quality of life among colorectal cancer survivors.
- Trial name
- NCT07158671
- Testing
- Intervention Group
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- The Nethersole School of Nursing
Breast Cancer
Safety of Pregnancy in BRCA Mutated Breast Cancer Patients
The present study aims at refining the understanding of the effect of pregnancy on breast cancer outcomes in the specific population of BRCA mutated patients with known history of breast cancer.
- Trial name
- NCT03673306
- Testing
- Clinical outcomes
- Where
- 81 sites in United States, Argentina and 24 more
- Volunteers
- 4,732 people
- Sponsor
- Jules Bordet Institute